

AbbVie Inc.  
Form FWP  
May 06, 2015

Filed pursuant to Rule 433

Dated May 5, 2015

Issuer Free Writing Prospectus supplementing the

Preliminary Prospectus Supplement dated  
May 5, 2015 and the

Prospectus dated April 27, 2015  
Registration No. 333-203677

AbbVie Inc.

**Pricing Term Sheet**

**\$3,000,000,000 1.800% Senior Notes due 2018**

**\$3,750,000,000 2.500% Senior Notes due 2020**

**\$1,000,000,000 3.200% Senior Notes due 2022**

**\$3,750,000,000 3.600% Senior Notes due 2025**

**\$2,500,000,000 4.500% Senior Notes due 2035**

**\$2,700,000,000 4.700% Senior Notes due 2045**

**Terms Applicable to the Notes**

<b>Issuer:</b>	AbbVie, Inc.
<b>Trade Date:</b>	May 5, 2015
<b>Settlement Date:</b>	May 14, 2015 (T+7)
<b>Form of Offering:</b>	SEC Registered (Registration No. 333-203677)
<b>Joint Book-Running Managers:</b>	Morgan Stanley & Co. LLC ( <i>All Notes</i> )

Merrill Lynch, Pierce, Fenner & Smith

Incorporated (*All Notes*)

Barclays Capital Inc. (*All Notes*)

Deutsche Bank Securities Inc. (*All Notes*)

## Edgar Filing: AbbVie Inc. - Form FWP

Mitsubishi UFJ Securities (USA), Inc. (2018, 2025, 2035, 2045 Notes)

BNP Paribas Securities Corp. (2020, 2022, 2025, 2035 Notes)

Credit Suisse Securities (USA) LLC (2022 Notes)

HSBC Securities (USA) Inc. (2018, 2020, 2022, 2045 Notes)

Mizuho Securities USA Inc. (2018 Notes)

SG Americas Securities, LLC (2020, 2025, 2035, 2045 Notes)

### Co-Managers:

Mitsubishi UFJ Securities (USA), Inc. (2020, 2022 Notes)

BNP Paribas Securities Corp. (2018, 2045 Notes)

Credit Suisse Securities (USA) LLC (2018, 2020, 2025, 2035, 2045 Notes)

HSBC Securities (USA) Inc. (2025, 2035 Notes)

Mizuho Securities USA Inc. (2020, 2022, 2025, 2035, 2045 Notes)

SG Americas Securities, LLC (2018, 2022 Notes)

DNB Markets, Inc.

Lloyds Securities Inc.

RBC Capital Markets, LLC

Santander Investment Securities Inc.

Standard Chartered Bank

U.S. Bancorp Investments, Inc.

Wells Fargo Securities, LLC

The Williams Capital Group, L.P.

---

### Terms applicable to 1.800% Senior Notes due 2018

<b>Aggregate Principal Amount:</b>	\$3,000,000,000
<b>Final Maturity Date:</b>	May 14, 2018
<b>Public Offering Price:</b>	99.898%, plus accrued and unpaid interest, if any, from May 14, 2015
<b>Benchmark Treasury:</b>	0.750% due April 15, 2018

---

<b>Benchmark Treasury Price and Yield:</b>	99-10 1/4 / 0.985%
<b>Spread to Benchmark Treasury:</b>	T+85 bps
<b>Coupon:</b>	1.800%
<b>Yield to Maturity:</b>	1.835%
<b>Interest Payment Dates:</b>	May 14 and November 14, commencing November 14, 2015
<b>Day Count Convention:</b>	30 / 360
<b>Make Whole Call:</b>	Make-whole call at T+15 bps
<b>Special Mandatory Redemption:</b>	If the consummation of the Pharmacyclics acquisition does not occur on or before February 3, 2016 or the Issuer notifies the Trustee that the merger agreement has been terminated in accordance with its terms prior to the consummation of the Pharmacyclics acquisition, the Issuer will be required to redeem the notes at a redemption price equal to 101% of their principal amount plus accrued and unpaid interest, if any, to, but excluding the special mandatory redemption date
<b>CUSIP / ISIN:</b>	00287Y AN9 / US00287YAN94

---

**Terms applicable to 2.500% Senior Notes due 2020**

<b>Aggregate Principal Amount:</b>	\$3,750,000,000
<b>Final Maturity Date:</b>	May 14, 2020
<b>Public Offering Price:</b>	99.590%, plus accrued and unpaid interest, if any, from May 14, 2015
<b>Benchmark Treasury:</b>	1.375% due April 30, 2020
<b>Benchmark Treasury Price and Yield:</b>	99-07 / 1.538%
<b>Spread to Benchmark Treasury:</b>	T+105 bps
<b>Coupon:</b>	2.500%
<b>Yield to Maturity:</b>	2.588%
<b>Interest Payment Dates:</b>	May 14 and November 14, commencing November 14, 2015
<b>Day Count Convention:</b>	30 / 360
<b>Make Whole Call:</b>	Make-whole call at T+20 bps
<b>Par Call:</b>	On or after April 14, 2020
<b>Special Mandatory Redemption:</b>	If the consummation of the Pharmacyclics acquisition does not occur on or before February 3, 2016 or the Issuer notifies the Trustee that the merger agreement has been terminated in accordance with its terms prior to the consummation of the Pharmacyclics acquisition, the Issuer will be required to redeem the notes at a redemption price equal to 101% of their principal amount plus accrued and unpaid interest, if any, to, but excluding the special mandatory redemption date
<b>CUSIP / ISIN:</b>	00287Y AT6 / US00287YAT64

---

**Terms applicable to 3.200% Senior Notes due 2022**

<b>Aggregate Principal Amount:</b>	\$1,000,000,000
<b>Final Maturity Date:</b>	November 6, 2022
<b>Public Offering Price:</b>	99.803%, plus accrued and unpaid interest, if any, from May 14, 2015
<b>Benchmark Treasury:</b>	1.750% due April 30, 2022
<b>Benchmark Treasury Price and Yield:</b>	98-26+ / 1.930%
<b>Spread to Benchmark Treasury:</b>	T+130 bps
<b>Coupon:</b>	3.200%
<b>Yield to Maturity:</b>	3.230%

Edgar Filing: AbbVie Inc. - Form FWP

**Interest Payment Dates:**

May 6 and November 6, commencing November 6, 2015

<b>Day Count Convention:</b>	30 / 360
<b>Make Whole Call:</b>	Make-whole call at T+20 bps
<b>Par Call:</b>	On or after September 6, 2022
<b>Special Mandatory Redemption:</b>	If the consummation of the Pharmacyclics acquisition does not occur on or before February 3, 2016 or the Issuer notifies the Trustee that the merger agreement has been terminated in accordance with its terms prior to the consummation of the Pharmacyclics acquisition, the Issuer will be required to redeem the notes at a redemption price equal to 101% of their principal amount plus accrued and unpaid interest, if any, to, but excluding the special mandatory redemption date
<b>CUSIP / ISIN:</b>	00287Y AP4 / US00287YAP43

---

**Terms applicable to 3.600% Senior Notes due 2025**

<b>Aggregate Principal Amount:</b>	\$3,750,000,000
<b>Final Maturity Date:</b>	May 14, 2025
<b>Public Offering Price:</b>	99.825%, plus accrued and unpaid interest, if any, from May 14, 2015
<b>Benchmark Treasury:</b>	2.000% due February 15, 2022
<b>Benchmark Treasury Price and Yield:</b>	98-16 / 2.171%
<b>Spread to Benchmark Treasury:</b>	T+145 bps
<b>Coupon:</b>	3.600%
<b>Yield to Maturity:</b>	3.621%
<b>Interest Payment Dates:</b>	May 14 and November 14, commencing November 14, 2015
<b>Day Count Convention:</b>	30 / 360
<b>Make Whole Call:</b>	Make-whole call at T+25 bps
<b>Par Call:</b>	On or after February 14, 2025
<b>Special Mandatory Redemption:</b>	If the consummation of the Pharmacyclics acquisition does not occur on or before February 3, 2016 or the Issuer notifies the Trustee that the merger agreement has been terminated in accordance with its terms prior to the consummation of the Pharmacyclics acquisition, the Issuer will be required to redeem the notes at a redemption price equal to 101% of their principal amount plus accrued and unpaid interest, if any, to, but excluding the special mandatory redemption date
<b>CUSIP / ISIN:</b>	00287Y AQ2 / US00287Y AQ26

---

**Terms applicable to 4.500% Senior Notes due 2035**

<b>Aggregate Principal Amount:</b>	\$2,500,000,000
<b>Final Maturity Date:</b>	May 14, 2035
<b>Public Offering Price:</b>	99.309%, plus accrued and unpaid interest, if any, from May 14, 2015
<b>Benchmark Treasury:</b>	3.000% due November 15, 2044
<b>Benchmark Treasury Price and Yield:</b>	101-29 / 2.903%
<b>Spread to Benchmark Treasury:</b>	T+165 bps
<b>Coupon:</b>	4.500%
<b>Yield to Maturity:</b>	4.553%
<b>Interest Payment Dates:</b>	May 14 and November 14, commencing November 14, 2015



**Day Count Convention:** 30 / 360  
**Make Whole Call:** Make-whole call at T+25 bps  
**Par Call:** On or after November 14, 2034  
**Special Mandatory Redemption:** If the consummation of the Pharmacyclics acquisition does not occur on or before February 3, 2016 or the Issuer notifies the Trustee that the merger agreement has been terminated in accordance with its terms prior to the consummation of the Pharmacyclics acquisition, the Issuer will be required to redeem the notes at a redemption price equal to 101% of their principal amount plus accrued and unpaid interest, if any, to, but excluding the special mandatory redemption date  
**CUSIP / ISIN:** 00287Y AR0 / US00287YAR09

---

**Terms applicable to 4.70% Senior Notes due 2045**

**Aggregate Principal Amount:** \$2,700,000,000  
**Final Maturity Date:** May 14, 2045  
**Public Offering Price:** 99.952%, plus accrued and unpaid interest, if any, from May 14, 2015  
**Benchmark Treasury:** 3.000% due November 15, 2044  
**Benchmark Treasury Price and Yield:** 101-29 / 2.903  
**Spread to Benchmark Treasury:** T+180 bps  
**Coupon:** 4.700%  
**Yield to Maturity:** 4.703%  
**Interest Payment Dates:** May 14 and November 14, commencing November 14, 2015  
**Day Count Convention:** 30 / 360  
**Make Whole Call:** Make-whole call at T+30 bps  
**Par Call:** On or after November 14, 2044  
**Special Mandatory Redemption:** If the consummation of the Pharmacyclics acquisition does not occur on or before February 3, 2016 or the Issuer notifies the Trustee that the merger agreement has been terminated in accordance with its terms prior to the consummation of the Pharmacyclics acquisition, the Issuer will be required to redeem the notes at a redemption price equal to 101% of their principal amount plus accrued and unpaid interest, if any, to, but excluding the special mandatory redemption date  
**CUSIP / ISIN:** 00287Y AS8 / US00287YAS81

---

The Issuer has filed a registration statement (including a preliminary prospectus supplement and an accompanying prospectus) with the Securities and Exchange Commission ( SEC ) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents that the Issuer has filed with the SEC, including the preliminary prospectus supplement, for more complete information about the Issuer and this offering. You may get these documents for free by visiting the SEC website at [www.sec.gov](http://www.sec.gov). Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus supplement and the accompanying prospectus if you request it by contacting Morgan Stanley & Co. LLC toll-free at (866) 718-1649; Barclays Capital Inc. toll-free at (888) 603-5847; Deutsche Bank Securities Inc. toll-free at (800) 503-4611 or Merrill Lynch Fenner & Smith Incorporated toll-free at (800) 294-1322.

Terms used but not defined herein shall have the meanings ascribed thereto in the Issuer's preliminary prospectus supplement, dated May 5, 2015, to the Issuer's prospectus, dated April 27, 2015.

